Kestra Private Wealth Services LLC Invests $215,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Kestra Private Wealth Services LLC acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 3,096 shares of the medical equipment provider’s stock, valued at approximately $215,000.

Other hedge funds have also recently made changes to their positions in the company. Covestor Ltd raised its holdings in shares of Lantheus by 102.5% during the second quarter. Covestor Ltd now owns 324 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 164 shares during the last quarter. First Horizon Advisors Inc. raised its holdings in shares of Lantheus by 97.0% during the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 225 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Lantheus by 60.2% during the second quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 160 shares during the last quarter. Quadrant Capital Group LLC raised its holdings in shares of Lantheus by 115.7% during the second quarter. Quadrant Capital Group LLC now owns 496 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 266 shares during the last quarter. Finally, NBC Securities Inc. purchased a new stake in Lantheus during the third quarter valued at approximately $46,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Mary Anne Heino sold 11,780 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $63.72, for a total transaction of $750,621.60. Following the completion of the transaction, the chief executive officer now owns 317,687 shares in the company, valued at $20,243,015.64. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, President Paul Blanchfield sold 1,500 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $67.96, for a total transaction of $101,940.00. Following the completion of the transaction, the president now owns 88,651 shares in the company, valued at $6,024,721.96. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Mary Anne Heino sold 11,780 shares of the stock in a transaction on Monday, November 13th. The shares were sold at an average price of $63.72, for a total transaction of $750,621.60. Following the transaction, the chief executive officer now owns 317,687 shares of the company’s stock, valued at approximately $20,243,015.64. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,962 shares of company stock worth $893,338. 1.50% of the stock is owned by insiders.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $56.14 on Friday. The company has a debt-to-equity ratio of 0.80, a current ratio of 5.37 and a quick ratio of 5.05. The firm has a fifty day moving average price of $60.77 and a 200-day moving average price of $65.79. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $100.85. The stock has a market cap of $3.85 billion, a PE ratio of 39.26 and a beta of 0.53.

Analyst Upgrades and Downgrades

A number of analysts have commented on LNTH shares. William Blair cut shares of Lantheus from an “outperform” rating to a “market perform” rating in a report on Monday, December 18th. TD Cowen started coverage on shares of Lantheus in a report on Monday, December 4th. They set an “outperform” rating and a $100.00 target price for the company. StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. B. Riley reduced their target price on shares of Lantheus from $113.00 to $95.00 and set a “buy” rating for the company in a report on Wednesday, January 10th. Finally, Brookline Capital Management began coverage on shares of Lantheus in a report on Thursday, November 30th. They set a “buy” rating and a $100.00 target price for the company. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $108.14.

Read Our Latest Research Report on LNTH

Lantheus Company Profile

(Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.

Further Reading

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.